said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.Amylyx also said Thursday it will lay off 70% of its more than 350 employees as part of a major restructuring effort.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:
España Últimas Noticias, España Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
Fuente: AP - 🏆 728. / 51 Leer más »
Amylyx Pharmaceuticals to Remove ALS Drug from MarketAmylyx Pharmaceuticals has announced that it will voluntarily remove its drug for amyotrophic lateral sclerosis (ALS) from the market. This decision comes after a recent clinical trial showed that the treatment is ineffective.
Fuente: washingtonpost - 🏆 95. / 72 Leer más »
Amylyx Pharmaceuticals to Pull Drug for Lou Gehrig’s Disease from MarketAmylyx said last month it was considering pulling its drug Relyvrio after a clinical trial in 600 patients failed to show any improvements in survival or other health measures. The maker of the drug has now announced that it will voluntarily halt sales and marketing of the drug, acknowledging its lack of effectiveness in helping patients with the deadly neurological condition.
Fuente: nbcsandiego - 🏆 524. / 51 Leer más »